| HOME >> BIOLOGY >> TECHNOLOGY |
NEW YORK and BARCELONA, Spain, May 15 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX), and Laboratorios Almirall, S.A. (ALM.MC) will host a webcast to discuss aclidinium bromide clinical and pre-clinical data findings presented at the American Thoracic Society Annual Congress. The webcast, which will include a slide presentation and a Q&A session, will occur on Wednesday, May 21, 2008 at 9:30am New York time, 3:30pm CET, 2:30pm UKT.
(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )
Representing Almirall will be Per-Olof Andersson, Executive Director,
Research and Development, Gonzalo de Miquel, Global Medical Director and
Jordi Beleta, Director of Biology of Almirall. Representing Forest
Laboratories will be Dr. Lawrence Olanoff, President and Chief Operating
Officer of Forest.
The webcast can be accessed at the URL: http://phx.corporate-ir.net/phoenix.zhtml?p=irol- eventDetails&c=83198&eventID=1853706 (Due to the length of the link, please copy and paste into your browser.)
Live audio-only access to the webcast can be obtained by dialing the
following phone numbers:
For U.S. participants: 866.831.6162
For all international participants: +617.213.8852
The webcast will be available on Forest Laboratories' and Almirall's websites at http://www.frx.com and http://www.almirall.com the same date.
A replay of the webcast will be available on both websites.
An audio-only replay will be available until May 28, 2008 and can be
accessed by dialing the following phone numbers: The passcode is 52634048
For U.S. participants: 888-286-8010
For all international participants: + 617-801-6888
'/>"/>
| SOURCE Forest Laboratories, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement
2. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
3. Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
4. Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement
5. Forest and Cypress Announce Submission of New Drug Application for Milnacipran for the Treatment of Fibromyalgia Syndrome
6. BioSpace Launches 3rd Edition of BioForest(TM) Bioscience Marketing Campaign
7. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
8. Nanotube forests grown on silicon chips for future computers, electronics
9. Forest Laboratories Lexapro and Generics-Dominated Fluoxetine Lead First-Line Therapy in the Treatment for Major Depression
10. Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
11. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |